学术探索
学术期刊
新闻热点
数据分析
智能评审

Soluble mesothelin-related protein - A blood test for mesothelioma

被引：77
作者：
Robinson, BWS
Creaney, J
Lake, R
Nowak, A
Musk, AW
de Klerk, N
Winzell, P
Hellstrom, KE
Hellstrom, I
机构：
[1] Univ Western Australia, Dept Med, Queen Elizabeth II Med Ctr, Nedlands, WA 6009, Australia
[2] Queen Elizabeth II Med Ctr, Western Australia Inst Med Res, Perth, WA, Australia
[3] Queen Elizabeth II Med Ctr, Sir Charles Gairdner Hosp, Dept Resp Med, Perth, WA, Australia
[4] UWA Ctr Child Hlth Res, Subiaco, WA, Australia
[5] Telethon Inst Child Hlth Res, Subiaco, WA, Australia
[6] Pacific NW Res Inst, Seattle, WA USA
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
mesothelioma; SMRP; SMRP assay; serum markers;
D O I：
10.1016/j.lungcan.2005.03.020
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Identification of tumor marker for mesothelioma (MM) might prove useful in diagnosis as well as for monitoring tumor in response to therapy and for screening at-risk individuals. We tested the hypothesis that soluble mesothelin-related protein (SMRP), a mesothelin family member, in the serum would be such a marker. Our data show that determination of SMRP in serum is a marker of MM with a sensitivity of sensitivity 83% and specificity 95% in the first 48 MM patients tested. Changes in serum SMRP levels parallel clinical course/tumor size and SMRP is elevated in 75% of patients at diagnosis. SMRP should also be useful for monitoring disease progression, and importantly, may prove useful for screening asbestos-exposed individuals for early MM. Crown Copyright (c) 2005 Published by Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：S109 / S111
页数：3
相关论文
共 23 条
[11]  
Ho L, 2001, Cancer Treat Res, V105, P327
[12]  
Johnson P J, 2001, Clin Liver Dis, V5, P145, DOI 10.1016/S1089-3261(05)70158-6
[13]   MOLECULAR-CLONING AND EXPRESSION OF MEGAKARYOCYTE POTENTIATING FACTOR CDNA [J].
KOJIMA, T ;
OHEDA, M ;
HATTORI, K ;
TANIGUCHI, Y ;
TAMURA, M ;
OCHI, N ;
YAMAGUCHI, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (37) :21984-21990
[14]   Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation [J].
Mukherjee, S ;
Haenel, T ;
Himbeck, R ;
Scott, B ;
Ramshaw, I ;
Lake, RA ;
Harnett, G ;
Phillips, P ;
Morey, S ;
Smith, D ;
Davidson, JA ;
Musk, AW ;
Robinson, B .
CANCER GENE THERAPY, 2000, 7 (05) :663-670
[15]   New approaches for mesothelioma: Biologics, vaccines, gene therapy, and other novel agents [J].
Nowak, AK ;
Lake, RA ;
Kindler, HL ;
Robinson, BWS .
SEMINARS IN ONCOLOGY, 2002, 29 (01) :82-96
[16]  
Olt G, 1990, Obstet Gynecol Surv, V45, P570, DOI 10.1097/00006254-199009000-00002
[17]   Appropriateness of prostate-specific antigen testing [J].
Poteat, HT ;
Chen, P ;
Loughlin, KR ;
Winkelman, JW ;
Allada, R ;
Ma'luf, N ;
Tanasijevic, MJ ;
Bates, DW .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 113 (03) :421-428
[18]   Mesothelin-family proteins and diagnosis of mesothelioma [J].
Robinson, BWS ;
Creaney, J ;
Lake, R ;
Nowak, A ;
Musk, AW ;
de Klerk, N ;
Winzell, P ;
Hellstrom, KE ;
Hellstrom, I .
LANCET, 2003, 362 (9396) :1612-1616
[19]   Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically [J].
Rusch, VW ;
Venkatraman, ES .
ANNALS OF THORACIC SURGERY, 1999, 68 (05) :1799-1804
[20]   Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma [J].
Scholler, N ;
Fu, N ;
Yang, Y ;
Ye, ZM ;
Goodman, GE ;
Hellström, KE ;
Hellström, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (20) :11531-11536
123